

India


HOLD (no change)

Sell 6 Consensus ratings*: Buy 23 Hold 14 Current price: Rs517 Rs550 Target price: Previous target: Rs550 Up/downside: 6.4% InCred Research / Consensus: -7.6% MRCO.NS Reuters: MRCO IN Bloombera: US\$8,039m Market cap: Rs668,404m US\$10.5m Average daily turnover: Rs873.1m Current shares o/s: 1,291.2m Free float: 40.6%

Key changes in this note

*Source: Bloomberg

- ➤ Lower FY24F/25F sales by 2.3%/2.2%.
- Lower FY24F/25F EBITDA margin by 10bp each.



		Source: Bloomberg		
Price performance	1M	ЗМ	12M	
Absolute (%)	(5.8)	(3.9)	2.5	
Relative (%)	(6.6)	(15.7)	(14.2)	

Major shareholders	% held
Promoter	59.4
First State Investments ICVC	4.7
LIC	3.9

Research Analyst(s)



Rohan KALLE

T (91) 22 4161 1561

E rohan.kalle@incredresearch.com

Nishant BAGRECHA

T (91) 22 4161 1564

E nishant.bagrecha@incredresearch.com

Marico Ltd

Corrective measures in the right direction

- Domestic 3Q sales volume/value remained subdued at 2%/ (8.4%) yoy, impacted by weak consumption and increased aggression from local players.
- FY24F gross/EBITDA margin guidance was upgraded further by 100/50bp, respectively. The diversified biz now clocks a higher blended gross margin.
- Marico is fairly priced at 48x/43x FY24F/25F P/E, respectively. We maintain our HOLD rating on it with a target price of Rs550 (41x Dec 2025F EPS).

Positive growth trajectory expected from 4QFY24F

Marico's 3QFY24 domestic sales declined by 8.4% yoy, which its management attributed to lower consumption, aggression by smaller payers in mass categories and a drop in sell-through rate or STR in retail channels. Volume growth stood at 2%. Parachute rigids reported +3%/flat volume/value growth, respectively, while the Saffola edible oils range declined by 26%. VAHO posted a 3% yoy value growth. The foods business grew by 18% yoy in 3Q and is expected to close FY24F at around Rs7.5bn. Marico has been taking corrective steps to alleviate challenges in its general trade channel by inventory reduction and it plans to further boost the channel going ahead through trade schemes, promotions, etc. Management highlighted its diversification journey in two avenues - driving up gross margin in the foods business and reducing cash burn in digital channels, with one or two of its digital brands set to achieve breakeven by the end of FY24F.

Bangladesh drags IBD sales growth; better growth likely in 4QFY24F

The international business division or IBD posted a 6% constant currency (CC) growth in 3QFY24. Bangladesh sales declined by 6% yoy in constant currency or CC terms owing to elections. Vietnam business grew 4% yoy in CC terms while South Africa and the MENA region grew 33%/26% yoy in CC terms, respectively. Management is confident of driving double-digit CC growth for the IBD in FY24F. Reported sales were affected by currency depreciation in key markets.

Upgrades margin guidance once again for FY24F

Consolidated gross margin/EBITDA margin expanded by 630bp/270bp yoy to 51.3%/21.2%, respectively, in 3QFY24, benefitting from deflationary commodity prices. Prices of copra are likely to remain firm, with an upward bias. Management has upgraded its guidance on gross margin to 450-500bp yoy expansion in FY24F (from 350-400bp yoy expansion earlier). The rising contribution of high-growth portfolio (foods, personal care & D2C) may restrict the EBITDA margin expansion, in our view.

Fairly priced; maintain HOLD rating with a target price of Rs550

At the current level, Marico looks fairly priced. We retain our HOLD rating on the stock with an unchanged target price of Rs550 (41x Dec 2025F EPS). Upside risks: Faster recovery in the core portfolio and sustained higher margins. Downside risk: Slower-than-expected sales growth.

Financial Summary	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue (Rsm)	95,120	97,640	99,810	112,921	124,076
Operating EBITDA (Rsm)	16,810	18,100	20,656	22,596	25,175
Net Profit (Rsm)	11,270	11,580	14,258	15,483	17,270
Core EPS (Rs)	8.7	9.0	11.1	12.0	13.4
Core EPS Growth	(3.0%)	2.8%	23.1%	8.6%	11.5%
FD Core P/E (x)	59.13	57.55	46.74	43.04	38.59
DPS (Rs)	6.0	6.0	6.3	6.7	7.4
Dividend Yield	1.35%	1.37%	1.43%	1.51%	1.67%
EV/EBITDA (x)	39.16	36.43	31.17	28.23	25.06
P/FCFE (x)	68.56	99.02	30.08	51.86	44.04
Net Gearing	(25.9%)	(21.7%)	(54.7%)	(60.4%)	(66.3%)
P/BV (x)	20.09	17.54	15.60	13.84	12.27
ROE	34.4%	32.5%	35.3%	34.1%	33.7%
% Change In Core EPS Estimates			(4.65%)	(5.50%)	(5.35%)
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS



Corrective measures in the right direction

Key takeaways from the earnings call

Demand and operating environment

- Demand: The FMCG industry's four-year volume CAGR was in the low single digits. The pace of recovery in consumption hasn't been on the anticipated lines. The consumption growth pattern seems to be K-shaped, as per management.
- Volume growth was up 2%. Primary levels were lowered to improve distributors' Return on Investment or Rol. More than 75% of the business gained market share.
- Initiatives in general trade channel: The focus is on improving distributors' Rol and ensure that they can pass on better credit to trade so that trade STRs can go up. The focus now is to reduce inventory and drive offtakes. The channel inventory correction is the first step. More initiatives are planned over the next few quarters (like trade schemes, promotions or retailer programs). Resource allocation will be done to ensure the trade channel delivers better service levels and expands the distribution reach.
- The core portfolio posted mid-single digit growth. Honey is the only category not doing well, largely due to a delayed winter.
- **Diversification journey**: It has been reasonably good. 1) Marico wanted to scale in a profitable manner. 2) Urban growth rate (which was strong during the Covid-19 pandemic) has tapered off. Aiming at 2x the scale over the next few years from the current level.

Segment-wise commentary

- Saffola edible oil: The brand exercised caution across channels to maintain its margin threshold. Edible oils are expected to revert to a growth trajectory in 4QFY24F.
- **VAHO:** Mid-to-high single digit growth in the range excluding the mass-end. The focus is on growing the mid-premium and premium-end going ahead.
- **Parachute:** Loose to branded conversions picked up pace as copra prices demonstrated an upward bias. The positive volume trend is expected to sustain for the next few quarters.
- **Food:** Should close the year at Rs7.5bn in revenue, as per management.
 - Going ahead, the food play will be strengthened with True Elements at the premium- end, Saffola at the masstige-end and Plix in the wellness space.
 - Management expects c.15-20% growth in the food business going ahead.
- **Digital portfolio and premium personal care:** This segment sustained its double-digit growth momentum. Male grooming and body lotion products dragged the overall sales growth.
- Acquired brands: Beardo will be EBITDA-positive by FY24F, and Just Herbs
 True Elements will move towards breakeven.
 - True Elements: Packaged foods have a significant opportunity. True Elements operates in the healthy food segment. Once Marico takes over a brand, the trajectory of growth improves as the brand gets a distribution bump (not yet done in True Elements). Going ahead, Saffola Food will play at the masstige-end while True Elements will operate at the premium-end.
 - Plix: This brand operates in the wellness space, where there are multiple vectors of growth like gut health, bone health, etc. Management believes it's a Rs2bn opportunity.
 - There is enough general trade or GT potential to scale digital brands in the future in a profitable manner, as per management.



International business:

- **Bangladesh** Newer portfolios fared better in 3QFY24 while the core portfolio was impacted due to elections in the country.
- Vietnam A modest quarter due to sluggish growth in the HPC category.
- MENA Both Egypt and Gulf regions drove growth.
- Margins: There were some issues around currency deflation. Marico is doing well in MENA and African markets. The endeavour is to deliver double-digit bottom-line growth.

Input costs and margins


- The diversified part of the business now has a higher blended gross margin than the core portfolio. With better efficiency in spending, Marico is able to drive double-digit EBITDA margin in newer businesses.
- Copra prices are likely to remain firm, with an upward bias. Edible oils aren't expected to decline further. From 1QFY25F, anniversarization of edible oils will be over. VAHO may see price hikes depending on the movement in crude oil prices.

Outlook


- Marico initiated corrective measures to improve growth in the general trade or GT channel to bring it back on track and drive volume growth in the core (mass) categories. The improving offtake growth will be led by growth in both primary and secondary channels (the Parachute brand is now demonstrating a similar trend).
- A slight revenue uptick is likely in 4QFY24F. Pricing growth may taper further in 4QFY24F. Some pricing interventions were done in Parachute to drive the volume higher.
- Gross/EBITDA margins guidance has been upgraded by 100/50bp yoy, respectively, for FY24F. The focus will be on delivering sustainable volumeled growth. Management expects positive all-round growth from 3QFY25F.

Figure 1: Quarterly results summary - consolidated								
Y/E Mar (Rs. m)	3QFY23	2QFY24	3QFY24	YoY (%)	QoQ (%)	9MFY23	9MFY24	Gr (%)
Revenue	24,700	24,760	24,220	-1.9	-2.2	75,240	73,750	-2.0
Expenditure	20,140	19,790	19,090	-5.2	-3.5	61,070	57,910	-5.2
Consumption of RM	13,600	12,260	11,800	-13.2	-3.8	41,730	36,450	-12.7
as % of sales	55.1	49.5	48.7			55.5	49.4	
Employee Costs	1,600	1,870	1,890	18.1	1.1	4,820	5,570	15.6
as % of sales	6.5	7.6	7.8			6.4	7.6	
Other Expenditure	4,940	5,660	5,400	9.3	-4.6	14,520	15,890	9.4
as % of sales	20.0	22.9	22.3			19.3	21.5	
EBITDA	4,560	4,970	5,130	12.5	3.2	14,170	15,840	11.8
Depreciation	390	390	420	7.7	7.7	1,120	1,170	4.5
EBIT	4,170	4,580	4,710	12.9	2.8	13,050	14,670	12.4
Other Income	400	380	430	7.5	13.2	760	1,270	67.1
Interest	140	200	190	35.7	-5.0	390	560	43.6
PBT	4,430	4,760	4,950	11.7	4.0	13,420	15,380	14.6
Total Tax	1,100	1,160	1,090	-0.9	-6.0	3,250	3,560	9.5
PAT	3,330	3,600	3,860	15.9	7.2	10,170	11,820	16.2
(Profit)/loss from JVs/Asso./MI	50	70	30	-40.0	-57.1	170	190	11.8
APAT after Minority Interest	3,280	3,530	3,830	16.8	8.5	10,000	11,630	16.3
Extraordinary items	0	0	0	NA	NA	0	0	NA
Reported PAT	3,280	3,530	3,830	16.8	8.5	10,000	11,630	16.3
EPS	2.5	2.7	3.0	16.8	8.5	7.8	9.0	16.3
Margins (%)	20EV22	20EV24	20EV24	VaV (hm)	QoQ (bp)	OMEVOS	9MFY24	/h-m\
	44.9	50.5	51.3	630	404 (bp)	44.5	50.6	(bp) 600
Gross margin EBITDA	18.5	20.1	21.2	270	110	18.8	21.5	260
EBIT	16.9	18.5	19.4	260	90	17.3	19.9	250
EBT	17.9	19.2	20.4	250	120	17.8	20.9	300
PAT	13.5	14.5	15.9	250	140	13.5	16.0	250
Effective Tax Rate	24.8	24.4	22.0	-280	-230	24.2	23.1	-110
LITECTIVE TAX INDIE	24.0	24.4	22.0				ZS. I COMPANY RE	























Figure 11: Gross/EBITDA margin guidance upgraded by 100/50bp yoy, respectively for FY24F India Vol. Growth - Expect Gradual Uptick Ahead International Business (CCG) - Going Strong India – Diversification Journey Double-digit CCG momentum likely to continue ~20% 16% 13% ~11% FY22 FY23 FY24E FY22 FY23 FY24E While recovery in volume growth has been slower than Revenue share of Foods & Premium Personal Care 9MFY24 CCG stood just shy of double digits due to anticipated, we expect gradual uptick ahead was at 20% of domestic business in Q3FY24 transient headwinds in select markets during Q3 **Gross Margin continues to trend higher** Highest-ever Operating Margin likely in FY24 A&P as a % of sales – Key Thrust for Growth + c.250 bps 450-500 bps potential potential 9.5%+ 45 2% 18.5% 17.7% FY22 FY23 FY24E FY22 FY23 FY24E EBITDA margin expected to expand by GM expansion higher than earlier envisaged owing to A&P spends ramped up to drive long-term growth moderation in RM prices and favourable portfolio mix c.250 bps in FY24 in core and new franchises SOURCE: INCRED RESEARCH, COMPANY REPORT

V/E M (D- M)		FY24F			FY25F			FY26F	
Y/E, Mar (Rs. M)	Earlier	Revised	% Change	Earlier	Revised	% Change	Earlier	Revised	% Change
Net Sales	102,127	99,810	-2.3	115,450	112,921	-2.2	126,796	124,076	-2.1
EBITDA	21,235	20,656	-2.7	23,196	22,596	-2.6	25,827	25,175	-2.5
EBITDA Margin (%)	20.8	20.7	-10 bp	20.1	20.0	-10 bp	20.4	20.3	-10 bp
Net Income (before exceptional items)	14,954	14,258	-4.7	16,383	15,483	-5.5	18,247	17,270	-5.4
EPS	11.6	11.1	-4.7	12.7	12.0	-5.5	14.1	13.4	-5.4





BY THE NUMBERS





(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Net Revenues	95,120	97,640	99,810	112,921	124,076
Gross Profit	40,760	44,130	49,311	55.515	61,796
Operating EBITDA	16,810	18,100	20,656	22,596	25,175
Depreciation And Amortisation	(1,390)	(1,550)	(1,753)	(1,957)	(2,160)
Operating EBIT	15,420	16,550	18,903	20,640	23,015
Financial Income/(Expense)	(390)	(560)	291	131	183
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)					
Profit Before Tax (pre-EI)	15,030	15,990	19,194	20,771	23,198
Exceptional Items					
Pre-tax Profit	15,030	15,990	19,194	20,771	23,198
Taxation	(3,460)	(4,210)	(4,636)	(4,988)	(5,628)
Exceptional Income - post-tax					
Profit After Tax	11,570	11,780	14,558	15,783	17,570
Minority Interests	(300)	(200)	(300)	(300)	(300)
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	11,270	11,580	14,258	15,483	17,270
Recurring Net Profit	11,270	11,580	14,258	15,483	17,270
Fully Diluted Recurring Net Profit	11,270	11,580	14,258	15,483	17,270

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
EBITDA	16,810	18,100	20,656	22,596	25,175
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(3,460)	1,420	10,711	61	351
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	980	1,440	1,011	851	903
Net Interest (Paid)/Received	(390)	(560)	(720)	(720)	(720)
Tax Paid	(3,460)	(4,210)	(4,636)	(4,988)	(5,628)
Cashflow From Operations	10,480	16,190	27,022	17,800	20,082
Capex	(1,020)	(6,780)	(1,868)	(1,950)	(1,950)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	260	(2,680)	(3,000)	(3,000)	(3,000)
Cash Flow From Investing	(760)	(9,460)	(4,868)	(4,950)	(4,950)
Debt Raised/(repaid)					
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(12,170)	(5,820)	(9,528)	(10,047)	(11,105)
Preferred Dividends					
Other Financing Cashflow					
Cash Flow From Financing	(12,170)	(5,820)	(9,528)	(10,047)	(11,105)
Total Cash Generated	(2,450)	910	12,626	2,803	4,026
Free Cashflow To Equity	9,720	6,730	22,154	12,850	15,132
Free Cashflow To Firm	10,110	7,290	22,874	13,570	15,852

SOURCE: INCRED RESEARCH, COMPANY REPORTS



BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Cash And Equivalents	12,200	13,340	28,966	34,769	41,796
Total Debtors	6,520	10,150	4,499	5,090	5,590
Inventories	14,120	12,250	15,024	15,847	16,153
Total Other Current Assets	3,290	3,950	3,648	4,127	4,530
Total Current Assets	36,130	39,690	52,138	59,834	68,069
Fixed Assets	12,930	15,620	15,747	15,740	15,530
Total Investments	1,870	5,180	5,180	5,180	5,180
Intangible Assets	3,060	5,600	5,588	5,588	5,588
Total Other Non-Current Assets	730	(320)	(320)	(320)	(320)
Total Non-current Assets	18,590	26,080	26,195	26,188	25,978
Short-term Debt	3,450	4,730	4,730	4,730	4,730
Current Portion of Long-Term Debt					
Total Creditors	13,440	14,520	22,406	24,342	25,889
Other Current Liabilities					
Total Current Liabilities	16,890	19,250	27,136	29,072	30,619
Total Long-term Debt		20	20	20	20
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities					
Total Non-current Liabilities		20	20	20	20
Total Provisions	220	480	126	144	158
Total Liabilities	17,110	19,750	27,282	29,236	30,797
Shareholders Equity	33,170	37,990	42,720	48,155	54,321
Minority Interests	570	1,570	1,570	1,570	1,570
Total Equity	33,740	39,560	44,290	49,725	55,891

Key Ratios					
	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue Growth	18.2%	2.6%	2.2%	13.1%	9.9%
Operating EBITDA Growth	5.6%	7.7%	14.1%	9.4%	11.4%
Operating EBITDA Margin	17.7%	18.5%	20.7%	20.0%	20.3%
Net Cash Per Share (Rs)	6.78	6.66	18.77	23.27	28.72
BVPS (Rs)	25.71	29.45	33.12	37.33	42.11
Gross Interest Cover	39.54	29.55	26.25	28.67	31.97
Effective Tax Rate	23.0%	26.3%	24.2%	24.0%	24.3%
Net Dividend Payout Ratio	79.7%	78.6%	66.8%	64.9%	64.3%
Accounts Receivables Days	19.95	31.16	26.79	15.50	15.71
Inventory Days	85.21	89.94	98.57	98.14	93.77
Accounts Payables Days	83.19	95.36	133.45	148.62	147.19
ROIC (%)	56.7%	50.6%	86.8%	95.0%	108.7%
ROCE (%)	42.1%	40.6%	40.5%	39.9%	40.0%
Return On Average Assets	22.0%	20.5%	19.8%	19.0%	19.3%

Key Drivers					
	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Domestic revenue growth	18.4%	(0.3%)	(0.8%)	13.1%	9.7%
EBIDTA margin	17.7%	18.5%	20.7%	20.0%	20.3%

SOURCE: INCRED RESEARCH, COMPANY REPORTS



Personal Products | India Marico Ltd | January 29, 2024

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report



Personal Products | India Marico Ltd | January 29, 2024

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm
 performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.